• Teleflex swung to third-quarter 2026 GAAP diluted earnings from continuing operations of $1.30 per share from a year-earlier loss.
• Revenue from continuing operations edged higher to $567.8 million compared with a year earlier.
• The pending Acute Care and Interventional Urology sale targets completion by year-end 2026, but regulatory approval could push closing into 2027.
• Full-year 2026 GAAP diluted earnings guidance from continuing operations rose to $2.84–$3.09 per share.
• GAAP revenue growth guidance from continuing operations fell to 13.2%–14.2% due to changes in foreign exchange rates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105860613) on November 05, 2026, and is solely responsible for the information contained therein.